{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:16:58Z","timestamp":1788257818877,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","award":["212680"],"award-info":[{"award-number":["212680"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anai.2026.05.018","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:53:36Z","timestamp":1779429216000},"page":"329-339.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Depemokimab reduces asthma exacerbations similarly to other biologics"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ballew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Vinals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houcine","family":"El Alili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Jangra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Laliman-Khara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grammati","family":"Sarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vichiendilokkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.anai.2026.05.018_bib0001","first-page":"1","article-title":"The Global Asthma Report 2022","volume":"26","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.anai.2026.05.018_bib0002","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib0003","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib0004","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.anai.2026.05.018_bib0005","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3389\/fimmu.2019.01699","article-title":"Activation of resolution pathways to prevent and fight chronic inflammation: lessons from asthma and inflammatory bowel disease","volume":"10","author":"Barnig","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib0006","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","article-title":"Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma","volume":"6","author":"Ortega","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2026.05.018_bib0007","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2026.05.018_bib0008","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2147\/JAA.S321212","article-title":"Association between a Type 2 inflammatory disease burden score and outcomes among patients with asthma","volume":"14","author":"Price","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0009","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/02770903.2010.535879","article-title":"Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life","volume":"48","author":"Guilbert","year":"2011","journal-title":"J Asthma"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.anai.2026.05.018_bib0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","article-title":"The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA","volume":"17","author":"Suruki","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.anai.2026.05.018_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105919","article-title":"Multinational cohort study of mortality in patients with asthma and severe asthma","volume":"165","author":"Engelkes","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2026.05.018_bib0013","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed May 31 2025. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2025\/05\/GINA-Strategy-Report_2025-WEB-WMS.pdf."},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0014","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.anai.2026.05.018_bib0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.anai.2026.05.018_bib0016","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.018_bib0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"10.1016\/j.anai.2026.05.018_bib0018","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of Benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.anai.2026.05.018_bib0019","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.anai.2026.05.018_bib0020","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0021","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"24","key":"10.1016\/j.anai.2026.05.018_bib0022","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.018_bib0023","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: continuing controversies and recent developments","volume":"15","author":"Ades","year":"2024","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.anai.2026.05.018_bib0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma biologics: comparing trial designs, patient cohorts and study results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"175","key":"10.1016\/j.anai.2026.05.018_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.anai.2026.05.018_bib0026","article-title":"Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma","volume":"191","author":"Bateman","year":"2022","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.018_bib0027","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.anai.2022.12.018","article-title":"A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis","volume":"130","author":"Pitre","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"16","key":"10.1016\/j.anai.2026.05.018_bib0028","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.3390\/jcm13164750","article-title":"Biologics in T2 severe asthma: unveiling different effectiveness by real-world indirect comparison","volume":"13","author":"Riccardi","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.anai.2026.05.018_bib0029","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Canada: Cochrane; 2023. Accessed May 31 2025. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current ."},{"issue":"11","key":"10.1016\/j.anai.2026.05.018_bib0030","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anai.2026.05.018_bib0031","unstructured":"National Institute for Health and Care Excellence. Appraisal checklists, evidence tables, GRADE and economic profiles. 2025. Appendix H. Accessed June 1, 2025. Available at: https:\/\/www.nice.org.uk\/process\/pmg20\/resources\/appendix-h-appraisal-checklists-evidence-tables-grade-and-economic-profiles-pdf-8779777885."},{"key":"10.1016\/j.anai.2026.05.018_bib0032","unstructured":"Bujkiewicz S, Achana F, Papanikos T, Riley RD, Abrams K. NICE DSU technical support document 20: multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints. University of Sheffield; 2025. Accessed June 1, 2025 Available at: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list."},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0033","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.anai.2026.05.018_bib0034","unstructured":"Value Outcomes Spotlight. Methods explained: Multilevel Network Meta-Regression. Accessed June 1, 2025. Available at: https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/vos-archives\/issue\/view\/healthcare-systems-around-the-world\/multilevel-network-meta-regression."},{"issue":"30","key":"10.1016\/j.anai.2026.05.018_bib0035","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study","volume":"39","author":"Phillippo","year":"2020","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.anai.2026.05.018_bib47","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib48","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.05.018_bib0036","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.anai.2026.05.018_bib0037","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cea.12853","article-title":"Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials","volume":"47","author":"Cabon","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.05.018_bib0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.05.018_bib0039","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.05.018_bib0040","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/PPA.S198953","article-title":"Stone B. Patient and physician preferences for attributes of biologic medications for severe asthma","volume":"13","author":"Gelhorn","year":"2019","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.anai.2026.05.018_bib0041","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","article-title":"Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporos Int J"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0042","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J Asthma"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib0043","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","article-title":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions","volume":"129","author":"Oppenheimer","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"suppl 1","key":"10.1016\/j.anai.2026.05.018_bib0044","doi-asserted-by":"crossref","first-page":"A1380","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1380","article-title":"Exploring global geographic variation in exacerbation rates in randomized controlled trials of biologics in patients with severe asthma: a systematic literature review","volume":"211","author":"Jackson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib0045","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02264-2024","article-title":"What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study","volume":"65","author":"Bourdin","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2026.05.018_bib0046","article-title":"Impact of COVID-19 pandemic on asthma exacerbations: retrospective cohort study of over 500,000 patients in a national English primary care database","volume":"19","author":"Shah","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"2","key":"10.1016\/j.anai.2026.05.018_bib50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2026.05.018_bib52","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2026.05.018_bib53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.anai.2026.05.018_bib54","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"10056","key":"10.1016\/j.anai.2026.05.018_bib55","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.05.018_bib56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.05.018_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JAA.S240044","article-title":"Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)","volume":"13","author":"Panettieri","year":"2020","journal-title":"J Asthma Allergy"},{"issue":"10039","key":"10.1016\/j.anai.2026.05.018_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2026.05.018_bib59","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2026.05.018_bib60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:49:52Z","timestamp":1788256192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1081120626002188"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.05.018","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depemokimab reduces asthma exacerbations similarly to other biologics","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}